Archives
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Previous in vitro and in vivo studies have shown
2019-09-30

Previous in vitro and in vivo studies have shown the potent ability of toll-like receptor (TLR) ligands and type I interferon (IFN) signaling to induce CH25H in macrophages and DCs following exposure to innate immune stimuli (Bauman et al., 2009; Diczfalusy et al., 2009; Park and Scott, 2010; Zou et
-
94 8 pathway In all available E E structures the
2019-09-30

In all available E2:E3 structures, the RING-type domain binds the E2 on a surface that is remote from the active site Cys (and therefore from the ubiquitin thioester) (Fig. 2). The non-contiguous E3-binding and active sites on the E2 imply that the role played by a RING to facilitate ubiquitin trans
-
Introduction The term myeloproliferative disorders was
2019-09-30

Introduction The term “myeloproliferative disorders” was first proposed by William Dameshek in 1951. With the discovery of the Philadelphia chromosome, myeloproliferative disorders were classified into two groups: BCR-ABL positive chronic myeloid leukemia (CML) and BCR-ABL negative chronic myelopro
-
br Acknowledgments br Introduction Cysteinyl leukotrienes Cy
2019-09-30

Acknowledgments Introduction Cysteinyl leukotrienes (CysLTs), LTC4, LTD4 and LTE4, are 5-lipoxygenase pathway metabolites of arachidonic Pyrimethamine and and deeply involved in bronchial asthma via activation of CysLT1 receptors [1], [2]. Specific CysLT1 receptor antagonists, including pranl
-
To date methods for the simultaneous
2019-09-30

To date, methods for the simultaneous analysis of multiple probe drugs in the plasma have been described by using HPLC-DAD or LC–MS/MS. Although previous cocktail methods have used combinations of those four or other probe drugs with LC–MS/MS methods, most of those studies focused on only the analys
-
br Conclusion CSF R may contribute
2019-09-30

Conclusion CSF-1R may contribute to limitation of targeted therapies by providing EGFR-bypassing signals that support proliferation. Multi-kinase inhibitors such as cabozantinib are available, and agents targeting CSF-1R are in clinical trials, however, at present, as inhibitors of tumor-associat
-
Within the Class II receptors the Type I IFN
2019-09-30

Within the Class II receptors, the Type I IFN receptor subunit, IFNAR-1, is exceptional in having four tandem FNIII domains, denoted here D1–D4. This structure appears to have arisen as a tandem NU 1025 clinical of the basic D1/D2 structure; thus, D1 and D3 of IFNAR-1 are more closely related, as a
-
Primary renal PNET was first reported by Seemayer et al
2019-09-29

Primary renal PNET was first reported by Seemayer et al in 1975. The possible etiology of rPNET is based on the theory of neural cell intussusception in the kidney during development that initiates the tumorigenesis. rPNET most commonly affects young adults, with a mean age of 30.4 years and male pr
-
With regards to translational development of SMEPT we acknow
2019-09-29

With regards to translational development of SMEPT, we acknowledge that we are not aware of any trials currently underway to validate this methodology in clinical settings. It appears fair to say that enthusiasm and commitment from corporate developers does not match that of academic partners. One r
-
Another pathway that requires proper DUB
2019-09-29

Another pathway that requires proper DUB recruitment is the DNA damage response (DDR). After ultraviolet (UV)-induced DNA damage, monoubiquitylated proliferating cell nuclear antigen (PCNA) mediates signaling that leads to repair. The DUB complex USP1/USP1-associated factor 1 (UAF1) deubiquitylates
-
br Discussion Previous studies have reported conflicting ass
2019-09-29

Discussion Previous studies have reported conflicting association results between the functional variant DBH −1021C>T and PD [8], [9]. Our findings would suggest that DBH −1021C>T does not dramatically decrease the risk of disease although it may marginally affect symptomatic AAO. However, whethe
-
Expression of MGMT in human cells
2019-09-29

Expression of MGMT in human TW-37 can be switched off by enzymatic methylation of a cytosine residue in the MGMT promoter sequence. In this regard, both MGMT and the mismatch repair function MLH1 belong to a subset of DNA repair genes that are subjected to epigenetic control. In consequence, about
-
monocrotaline Since Slaughter s proposal of a genetic field
2019-09-29

Since Slaughter’s proposal of a genetic field defect concept for the explanation of the local relapse occurrence, much evidence has accumulated for its confirmation. The last ten years brought evidence that the genetic changes in the field are frequently accompanied by epigenetic aberrations. The ep
-
In addition we investigated if
2019-09-29

In addition, we investigated if the previously reported papain inhibitor can inhibit rhodesain, and found that it was not active at inhibiting rhodesain. The vinyl sulfone analogue of () was then synthesized and tested, and it was also inactive towards rhodesain. We then determined the time depend
-
Recent studies showed that the activity of
2019-09-29

Recent studies showed that the activity of CK2 was significantly reduced in ischemic stroke model rats, and cerebral I/R injury significantly decreased the expression of CK2α (Lee et al., 2004; Kim et al., 2012; Zhou et al., 2016). In addition, the dysregulation of CK2 is involved in ERS/UPR in non-
14494 records 955/967 page Previous Next First page 上5页 951952953954955 下5页 Last page